These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

141 related articles for article (PubMed ID: 38996148)

  • 1. Role of anagliptin, a dipeptidyl peptidase-4 inhibitor, in managing type 2 diabetes: A systematic review and meta-analysis.
    Kamrul-Hasan ABM; Dutta D; Nagendra L; Sharma M; Patra S; Bhattacharya S
    Medicine (Baltimore); 2024 Jul; 103(28):e38870. PubMed ID: 38996148
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Safety and efficacy of once weekly dipeptidyl-peptidase-4 inhibitor trelagliptin in type-2 diabetes: A meta-analysis.
    Dutta D; Mohindra R; Surana V; Sharma M
    Diabetes Metab Syndr; 2022 Apr; 16(4):102469. PubMed ID: 35344848
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Efficacy and Safety of the Novel Dipeptidyl Peptidase-4 Inhibitor Gemigliptin in the Management of Type 2 Diabetes: A Meta-Analysis.
    Dutta D; Agarwal A; Maisnam I; Singla R; Khandelwal D; Sharma M
    Endocrinol Metab (Seoul); 2021 Apr; 36(2):374-387. PubMed ID: 33820392
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Dipeptidyl peptidase-4 inhibitor anagliptin reduces fasting apolipoprotein B-48 levels in patients with type 2 diabetes: A randomized controlled trial.
    Onoue T; Goto M; Wada E; Furukawa M; Okuji T; Okada N; Kobayashi T; Iwama S; Sugiyama M; Tsunekawa T; Takagi H; Hagiwara D; Ito Y; Morishita Y; Seino Y; Suga H; Banno R; Hamada Y; Ando M; Yamamori E; Arima H
    PLoS One; 2020; 15(1):e0228004. PubMed ID: 31990936
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Anagliptin, A Dipeptidyl Peptidase-4 Inhibitor Ameliorates Arterial Stiffness in Association with Reduction of Remnant-Like Particle Cholesterol and Alanine Transaminase Levels in Type 2 Diabetic Patients.
    Tahara N; Yamagishi SI; Bekki M; Kodama N; Nakamura T; Sugiyama Y; Oshige T; Kumashiro Y; Honda A; Tahara A; Igata S; Fukumoto Y
    Curr Vasc Pharmacol; 2016; 14(6):552-562. PubMed ID: 27357182
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effect of Anagliptin and Sitagliptin on Low-Density Lipoprotein Cholesterol in Type 2 Diabetic Patients with Dyslipidemia and Cardiovascular Risk: Rationale and Study Design of the REASON Trial.
    Ueda S; Shimabukuro M; Arasaki O; Node K; Nomiyama T; Morimoto T
    Cardiovasc Drugs Ther; 2018 Feb; 32(1):73-80. PubMed ID: 29435776
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A randomized, placebo-controlled, double-blind, phase 3 trial to evaluate the efficacy and safety of anagliptin in drug-naïve patients with type 2 diabetes.
    Yang HK; Min KW; Park SW; Chung CH; Park KS; Choi SH; Song KH; Kim DM; Lee MK; Sung YA; Baik SH; Kim IJ; Cha BS; Park JH; Ahn YB; Lee IK; Yoo SJ; Kim J; Park IeB; Park TS; Yoon KH
    Endocr J; 2015; 62(5):449-62. PubMed ID: 25819061
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Glucose-lowering agents for treating pre-existing and new-onset diabetes in kidney transplant recipients.
    Lo C; Jun M; Badve SV; Pilmore H; White SL; Hawley C; Cass A; Perkovic V; Zoungas S
    Cochrane Database Syst Rev; 2017 Feb; 2(2):CD009966. PubMed ID: 28238223
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Treatment with anagliptin, a DPP-4 inhibitor, decreases FABP4 concentration in patients with type 2 diabetes mellitus at a high risk for cardiovascular disease who are receiving statin therapy.
    Furuhashi M; Sakuma I; Morimoto T; Higashiura Y; Sakai A; Matsumoto M; Sakuma M; Shimabukuro M; Nomiyama T; Arasaki O; Node K; Ueda S
    Cardiovasc Diabetol; 2020 Jun; 19(1):89. PubMed ID: 32539832
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Efficacy and Safety of Omarigliptin, a Novel Once-Weekly Dipeptidyl Peptidase-4 Inhibitor, in Type 2 Diabetes Mellitus: A Systematic Review and Meta-Analysis.
    Kamrul-Hasan ABM; Alam MS; Talukder SK; Dutta D; Selim S
    Endocrinol Metab (Seoul); 2024 Feb; 39(1):109-126. PubMed ID: 38417828
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Dipeptidyl-peptidase (DPP)-4 inhibitors and glucagon-like peptide (GLP)-1 analogues for prevention or delay of type 2 diabetes mellitus and its associated complications in people at increased risk for the development of type 2 diabetes mellitus.
    Hemmingsen B; Sonne DP; Metzendorf MI; Richter B
    Cochrane Database Syst Rev; 2017 May; 5(5):CD012204. PubMed ID: 28489279
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Differential Effects of DPP-4 Inhibitors, Anagliptin and Sitagliptin, on PCSK9 Levels in Patients with Type 2 Diabetes Mellitus who are Receiving Statin Therapy.
    Furuhashi M; Sakuma I; Morimoto T; Higashiura Y; Sakai A; Matsumoto M; Sakuma M; Shimabukuro M; Nomiyama T; Arasaki O; Node K; Ueda S
    J Atheroscler Thromb; 2022 Jan; 29(1):24-37. PubMed ID: 33342939
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Mechanism of lipid-lowering action of the dipeptidyl peptidase-4 inhibitor, anagliptin, in low-density lipoprotein receptor-deficient mice.
    Yano W; Inoue N; Ito S; Itou T; Yasumura M; Yoshinaka Y; Hagita S; Goto M; Nakagawa T; Inoue K; Tanabe S; Kaku K
    J Diabetes Investig; 2017 Mar; 8(2):155-160. PubMed ID: 27860391
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Anagliptin decreases serum lathosterol level in patients with type 2 diabetes: a pilot study.
    Aoki K; Ijima T; Kamiyama H; Kamiko K; Terauchi Y
    Expert Opin Pharmacother; 2015; 16(12):1749-54. PubMed ID: 26098722
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Differences in lipid metabolism between anagliptin and sitagliptin in patients with type 2 diabetes on statin therapy: a secondary analysis of the REASON trial.
    Chihara A; Tanaka A; Morimoto T; Sakuma M; Shimabukuro M; Nomiyama T; Arasaki O; Ueda S; Node K
    Cardiovasc Diabetol; 2019 Nov; 18(1):158. PubMed ID: 31733647
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Efficacy and safety of albiglutide, a once-weekly glucagon-like peptide-1 receptor agonist, in patients with type 2 diabetes: A systematic review and meta-analysis.
    Kamrul-Hasan ABM; Dutta D; Nagendra L; Bhattacharya S; Singla R; Kalra S
    Medicine (Baltimore); 2024 Jun; 103(25):e38568. PubMed ID: 38905435
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Insulin and glucose-lowering agents for treating people with diabetes and chronic kidney disease.
    Lo C; Toyama T; Wang Y; Lin J; Hirakawa Y; Jun M; Cass A; Hawley CM; Pilmore H; Badve SV; Perkovic V; Zoungas S
    Cochrane Database Syst Rev; 2018 Sep; 9(9):CD011798. PubMed ID: 30246878
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The efficacy and safety of dipeptidyl peptidase-4 inhibitors for type 2 diabetes: a Bayesian network meta-analysis of 58 randomized controlled trials.
    Ling J; Cheng P; Ge L; Zhang DH; Shi AC; Tian JH; Chen YJ; Li XX; Zhang JY; Yang KH
    Acta Diabetol; 2019 Mar; 56(3):249-272. PubMed ID: 30242726
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Efficacy and safety of dipeptidyl peptidase-4 inhibitors and metformin as initial combination therapy and as monotherapy in patients with type 2 diabetes mellitus: a meta-analysis.
    Wu D; Li L; Liu C
    Diabetes Obes Metab; 2014 Jan; 16(1):30-7. PubMed ID: 23803146
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Efficacy and safety of gemigliptin, a dipeptidyl peptidase-4 inhibitor, in patients with type 2 diabetes mellitus inadequately controlled with combination treatment of metformin and sulphonylurea: a 24-week, multicentre, randomized, double-blind, placebo-controlled study (TROICA study).
    Ahn CH; Han KA; Yu JM; Nam JY; Ahn KJ; Oh TK; Lee HW; Lee DH; Kim J; Chung CH; Park TS; Kim BJ; Park SW; Park HK; Lee KJ; Kim SW; Park JH; Ko KP; Kim CH; Lee H; Jang HC; Park KS
    Diabetes Obes Metab; 2017 May; 19(5):635-643. PubMed ID: 28026912
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.